Kyoto University trial of YStory-built JoyHer Pro app reports lower menopause scores, pending review
In a preprint dated Nov. 11, a Kyoto University-led team reports that women assigned the full JoyHer Pro app, built by YStory, had lower menopause symptom scores after 12 weeks than those given a limited version. YStory co-sponsored the trial; the paper is not yet peer reviewed.
Based on a preprint and a published study by Kyoto University-led researchers, a clinical trial registry entry, Japanese government documents, and company websites and announcements · Sources
Kyoto University-led researchers have reported results from a randomized controlled trial of JoyHer Pro, a menopause self-care app that Tokyo-based YStory Inc. developed with them. In a preprint dated Nov. 11, 2026, and submitted to the Journal of Medical Internet Research, they say women assigned the full app ended the 12-week trial with lower self-reported symptom scores than women given a limited version. The paper has not yet been peer reviewed.
On the trial’s main measure, the self-reported Menopause Rating Scale, which runs from 0 to 44, the JoyHer Pro group’s adjusted mean score at 12 weeks was 10.29, against 11.98 for the comparison group, a gap of 1.68 points (95% confidence interval 0.77 to 2.59). In a post hoc analysis of women with 12-week scores, 42.1% of the JoyHer Pro group and 26.9% of the comparison group improved by 5 points or more. No one spontaneously reported an adverse event linked to the intervention.
Both apps offered the same 58 educational topics, ranked by each woman’s symptoms. JoyHer Pro alone added daily symptom logging and reminders, and every two weeks it picked new self-care tips for each user automatically, with no clinician or researcher tailoring them. Its users logged in on a median of 16 days, versus five in the control group. Recruited online, participants were Japanese iPhone users aged 45 to 59 with irregular or no periods and a symptom score of at least 5; the registry excludes women with psychiatric disorders such as depression and those who had started hormone therapy or antidepressants within 30 days. The analysis covered 401 women: 197 on JoyHer Pro and 204 on the comparison app.
Caveats and conflicts
Open peer review runs until Jan. 7, 2027. Of the 584 women randomized, 183 were not analyzed because they did not download their app or did not complete the starting questionnaire. The trial’s entry in Japan’s UMIN Clinical Trials Registry lists Miho Egawa, a lecturer in obstetrics and gynecology at Kyoto University Hospital, as lead principal investigator, Kyoto University as sponsor, the Japan Science and Technology Agency as funder and YStory as co-sponsor. YStory made Egawa an academic adviser in October 2026, and its page for employers presents five of the authors, including Egawa and first author Takuma Ohsuga, as its joint-research members. Kyoto University Innovation Capital, the university’s wholly owned venture capital arm, led YStory’s pre-Series A round in April. Two of the 12 authors were listed under YStory in the team’s earlier paper. The results may not carry over to the apps YStory sells.
The earlier study, published in the journal Digital Health in June 2026, enrolled 91 employed women aged 45 to 55 with moderate symptoms in Nagahama, Shiga Prefecture; they used an earlier version of JoyHer Pro for six months, with researchers revising care plans monthly. The group’s median score on a 105-point Japanese symptom questionnaire fell from 33 to 26, but with no comparison group, the authors wrote, the study cannot show the app caused that. Funders were an education ministry grant, an economy ministry femtech subsidy and YStory, which helped manage the research but, the paper says, did not analyze or interpret the data.
Selling to employers
Founded in January 2023, YStory is led by representative directors Janet Yu and Sherry Shi. Its consumer app, JoyHer, offers symptom logging, educational material, a community where users can stay anonymous and self-care tips the company says are personalized with AI; it said in April that more than 70,000 people had downloaded the app. Its edition for employers and health insurance societies, launched in April 2026, includes an AI chat feature and gives employers only statistics that cannot identify individuals, the company’s website says. YStory’s terms of service say the JoyHer services do not diagnose illness or give medical advice.
Investors in YStory’s April round, whose size was not disclosed, also included ASKA Pharmaceutical’s corporate venture capital fund and existing investor ANRI. On Oct. 16, 2026, YStory said it had begun an exploratory study with Kyoto University Hospital’s obstetrics and gynecology department, text-mining JoyHer community posts to map women’s everyday health problems and latent needs.
The policy backdrop
In a 2022 survey by the Ministry of Health, Labour and Welfare, 38.3% of women in their 50s suspected menopausal disorder without a diagnosis, and 9.1% had been diagnosed. In January 2026, after an expert panel backed adding questions on painful periods, menopausal disorder and similar conditions to statutory workplace health checkups, the ministry issued manuals for checkup providers and employers. A February 2024 estimate by the Ministry of Economy, Trade and Industry, calculated by Boston Consulting Group, put the annual economic loss from menopausal symptoms at about ¥1.9 trillion.
Sources
- JMIR Preprints preprints.jmir.org
- UMIN Clinical Trials Registry center6.umin.ac.jp
- PubMed Central · PMC13254422 pmc.ncbi.nlm.nih.gov
- PubMed Central · PMC516787 pmc.ncbi.nlm.nih.gov
- YStory ystoryhealth.com
- Kyoto University Innovation Capital kyoto-unicap.co.jp
- PR TIMES · 000000024.000122669 prtimes.jp
- PR TIMES · 000000027.000122669 prtimes.jp
- PR TIMES · 000000012.000122669 prtimes.jp
- PR TIMES · 000000016.000122669 prtimes.jp
- JoyHer joyher.life
- JoyHer · terms-of-service joyher.life
- Ministry of Health, Labour and Welfare · 000969136.pdf mhlw.go.jp
- Ministry of Health, Labour and Welfare · newpage_68776 mhlw.go.jp
- METI meti.go.jp
Every article lists its sources · Editorial standards · Corrections: press@japantechdesk.com
Next storyALE redesigns its release device for a third attempt at artificial shooting stars in fiscal 2028